机构:[a]Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 10OO53, China首都医科大学宣武医院低氧医学研究室[b]Banyan Laboratories, Banyan Biomarkers Inc., Alachua, FL, USA[c]Xuanwu-Banyan Biomarker Research and Assay Center, Beijing 1OOO53, China[d]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA[e]Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 1OOO53, China神经外科首都医科大学宣武医院[f]Department of Psychiatry, Center for Neuroproteomics and Biomarkers Research, University of Florida, Gainesville, FL, USA
The two primary categories of stroke, ischemic and hemorrhagic, both have fundamentally different mechanisms and thus different treatment options. These two stroke categories were applied to rat models to identify potential biomarkers that can distinguish between them. Ischemic stroke was induced by middle cerebral artery occlusion (MCAO) without reperfusion while hemorrhagic stroke was induced by injecting collagenase IV into the striatum. Brain hemispheres and biofluids were collected at two time points: 3 and 6 h after stroke. Known molecules were tested on the rat samples via quantitative immunoblotting (injured brain, CSF) and Banyan's proprietary ELISA assays (CSF, serum). The injured brain quantitative analyses revealed that ell-spectrin breakdown products (SBDP150, SBDP145) were strongly increased after 6 h ischemia. In CSF, SBDP145 and ubiquitin C-terminal hydrolase-L1 (UCH-L1) levels were elevated after 6 h ischemic stroke detected by Western blot and ELISA. In serum UCH-L1 levels were increased after 3 and 6 h of ischemia detected by ELISA. However, levels of those proteins in hemorrhagic stroke remain normal. In summary, in both the brain and the biofluids, SBDPs and UCH-L1 were elevated after ischemic but not hemorrhagic stroke. These molecules behaved differently in the two stroke models and thus may be capable of being differentiated. (C) 2013 Elsevier B.V. All rights reserved.
基金:
the Program of National Natural Science Foundation of China(81171241)
the Program of Excellent Talents of Beijing(2011D005018000007)
第一作者机构:[a]Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 10OO53, China[c]Xuanwu-Banyan Biomarker Research and Assay Center, Beijing 1OOO53, China
共同第一作者:
通讯作者:
通讯机构:[*1]Department of Neurosurgery,Xuanwu Hospital,Capital Medical University,Chang Chun Road45,Beijing 100053,China
推荐引用方式(GB/T 7714):
Changhong Ren,Susie Zoltewicz,Joy Guingab-Cagmat,et al.Different expression of ubiquitin C-terminal hydrolase-L1 and alpha II-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis[J].BRAIN RESEARCH.2013,1540:84-91.doi:10.1016/j.brainres.2013.09.051.
APA:
Changhong Ren,Susie Zoltewicz,Joy Guingab-Cagmat,John Anagli,Mingqing Gao...&Yuchuan Ding.(2013).Different expression of ubiquitin C-terminal hydrolase-L1 and alpha II-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis.BRAIN RESEARCH,1540,
MLA:
Changhong Ren,et al."Different expression of ubiquitin C-terminal hydrolase-L1 and alpha II-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis".BRAIN RESEARCH 1540.(2013):84-91